Moleculin Raises $6.5 Million from Warrant Exercises—Fresh Capital and New Warrants Set the Stage for 2026
Market Chameleon (Wed, 10-Dec 9:02 AM)
Moleculin’s New Annamycin Brain Tumor Collaboration Targets Unmet Needs in Glioblastoma
Market Chameleon (Mon, 8-Dec 8:48 AM)
